PCT

NOTIFICATION CONCERNING
TRANSMITTAL OF COPY OF INTERNATIONAL
PRELIMINARY REPORT ON PATENTABILITY
(CHAPTER I OF THE PATENT COOPERATION
TREATY)

(PCT Rule 44bis.1(c))

From the INTERNATIONAL BUREAU

To: 10: 12 c

HGSI

COCHMAN, Christine, M. '-Leydig, Voit & Mayer, LTD. Two Prudential Plaza 180 N. Stetson Avenue Chicago, Illinois 60601-6731 ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year)
09 October 2008 (09.10.2008)

Applicant's or agent's file reference 702091

IMPORTANT NOTICE

International application No. PCT/US2007/008021

International filing date (day/month/year) 30 March 2007 (30.03.2007)

Priority date (day/month/year) 31 March 2006 (31.03.2006)

Applicant

HUMAN GENOME SCIENCES INC. et al

The International Bureau transmits herewith a copy of the international preliminary report on patentability (Chapter I of the Patent Cooperation Treaty)

LAH

JC

LEYDIG, VOIT & MAYER RECEIVED

OCT 2 9 2008

PAT/TM Due Date

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

Beate Giffo-Schmitt

Facsimile No. +41 22 338 82 70

e-mail: pt03.pct@wipo.int

Form PCT/IB/326 (January 2004)

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Appli 7020	cant's or agent's file reference 91	FOR FURTHER A	CTION	See item 4 below	
Intern PCT/	ational application No. US2007/008021	International filing date (day/mo 30 March 2007 (30.03.2007)	onth/year)	Priority date (day 31 March 2006	/month/year) (31.03.2006)
Intern See r	ational Patent Classification (8th relevant information in Form F	n edition unless older edition indie PCT/ISA/237	cated)		
Applio HUM	cant AN GENOME SCIENCES INC	C.			
				1 Att	LEYDIG, VOIT & MAYER RECEIVED
					OCT 2 9 2008
					PAY/TM Due Date
1.	This international preliminary International Searching Author	report on patentability (Chapter I rity under Rule 44 bis.1(a).) is issued by the I	nternational Burea	nu on behalf of the
2.	This REPORT consists of a to	tal of 4 sheets, including this cove	er sheet.		
	In the attached sheets, any refeto the international preliminary	erence to the written opinion of the yreport on patentability (Chapter	e International Sea I) instead.	arching Authority s	should be read as a reference
3.	This report contains indication	s relating to the following items:			
	Box No. I	Basis of the report			
	Box No. II	Priority			
	Box No. III	Non-establishment of opinio applicability	n with regard to no	ovelty, inventive s	tep and industrial
	Box No. IV	Lack of unity of invention			
	Box No. V	Reasoned statement under A applicability; citations and e	rticle 35(2) with rexplanations suppor	egard to novelty, in	nventive step or industrial nt
	Box No. VI	Certain documents cited			
	Box No. VII	Certain defects in the interna	tional application		
	Box No. VIII	Certain observations on the i	nternational applic	cation	
4.	The International Bureau will onot, except where the applicant date (Rule 44bis .2).	communicate this report to design t makes an express request under	ated Offices in acc Article 23(2), befo	cordance with Rule ore the expiration of	es 44 <i>bis</i> .3(c) and 93 <i>bis</i> .1 but of 30 months from the priority
		F	Nata - 6:	41.	
			Date of issuance of 30 September 20		·
	The International Bur 34, chemin des Co	reau of wiPO	Authorized officer		
	1211 Geneva 20, S	•		Beate Giffo-	-Schmitt
Facsin	nile No. +41 22 338 82 70	ه ا	_mail: nt03 nct@n	vino int	

Form PCT/IB/373 (January 2004)

PATENT COOPERATION TREATY

From the INTERNATION	ONAL SEARCI	HING AUTH	ORITY		
LEYDIG, V TWO PRUI 180 N. STE	E M. COCHRA OIT & MAYEI DENTIAL PLA TSON AVENU	R, LTD. ZA, SUITE 4 E	900		PCT RITTEN OPINION OF THE
CHICAGO,	, IL 60601-673	1		INTERNATI	ONAL SEARCHING AUTHORITY
					(PCT Rule 43bis.1)
				Date of mailing (day/month/year)	04 AUG 2008
Applicant's	or agent's file re	eference		FOR FURTHER	ACTION
705473-600					See paragraph 2 below
Internationa	l application No		International filing date	(day/month/year)	Priority date (day/month/year)
PCT/US07/0		· (TDC)	30 March 2007 (30.03.2		31 March 2006 (31.03.2006)
			or both national classificat		
IPC: C1 (2006.01)	12N 5/20(2006.	.01); C07K 16	5/00(2006.01);G01N 33/5	3	
USPC: 43	35/326,331,7.1;5	30/387.1,387	.3,388.1		
Applicant					
HUMAN GI	ENOME SCIEN	ICES, INC.		·	
1. This op	inion contains ir	ndications rela	ating to the following item	s:	
	Box No. I	Basis of the	opinion		
	Box No. II	Priority			
	Box No. III	Non-establis	shment of opinion with re	gard to novelty, inve	ntive step and industrial applicability
	Box No. IV	Lack of unit	ty of invention		
	Box No. V		atement under Rule 43bis.		o novelty, inventive step or industrial atement
	Box No. VI	Certain doc	uments cited		
	Box No. VII	Certain defe	ects in the international app	plication	
	Box No. VIII	Certain obse	ervations on the internation	nal application	
2 FUDT	HED ACTIO	N.T			
If a den Internat Authori	tional Prelimina ity other than thi	ntional prelim ry Examining is one to be t	g Authority ("IPEA") ex	cept that this does IPEA has notified the	be considered to be a written opinion of the not apply where the applicant chooses an ae International Bureau under Rule 66.1bis(b) ered.
IPEA a	written reply to	gether, where		ments, before the ex	PEA, the applicant is invited to submit to the piration of 3 months from the date of mailing whichever expires later.
For furt	ther options, see	Form PCT/IS	SA/220.		
3. For furt	her details, see r	notes to Form	PCT/ISA/220.		
			e en		
Ma Co P.C	nailing address o ail Stop PCT, Attn immissioner for Pa D. Box 1450 exandria, Virginia	: ISA/US Itents	Date of comple	tion of this opinion 8.07.2008)	Authorized officer Spul Officer Dong Jishing Telephone No. 571-272-1600
	n (571) 273-320				

Form PCT/ISA/237 (cover sheet) (April 2007)

PCT/US2007/008021 04.08.2008

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No	
PCT/US07/08021	

Box No. I Basis of this opinion	
1. With regard to the language, this opinion has been established on the basis of:	
the international application in the language in which it was filed	1
a translation of the international application into, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)). This opinion has been established taking into account the rectification of an obvious mistake authorized by or notified to this	
Authority under Rule 91 (Rule 43bis.1(a)) 3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, this opinion has been established on the basis of:	
a. type of material	
a sequence listing	
table(s) related to the sequence listing	
b. format of material	
on paper	l
in electronic form	
c. time of filing/furnishing	
contained in the international application as filed.	
filed together with the international application in electronic form.	
furnished subsequently to this Authority for the purposes of search.	١
4. In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.	
5. Additional comments:	

PCT/US2007/008021 04.08.2008

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US07/08021

Statement		
Novelty (N)	Claims NONE	YE
	Claims 1-10	NO
Inventive step (IS)	Claims Movin	
mvomive step (13)	Claims NONE Claims 1-10	YE
Industrial applicability (IA	,	
	Claims NONE	NO
Citations and explanations:		
•	cle 33(2) as being anticipated by Yu et al. (US 2005/0186637	,
2 of the reference). Additionally, Yu	Deposit No. PTA-1158 and PTA-3794, and the antibody secreteaches a monoclonal antibody comprising the VH domain of	eted by the hybridoma (claims
iain of SEQ ID NO:59, wherein both S	SEO ID NO:58 and 59 are 100% identical to the present SEO	1D NO.58 and 50 (claims 2.5)
reference). Further, Yu teaches that the	e antibody can be a chimeric antibody a humanized antibodi	v a single chain antihody or an
body fragment, and that and the antibo	dv can be labeled (claims 6-8 of the reference) Furthermore	e, Yu teaches a method of
body fragment, and that and the antibo	ody can be labeled (claims 6-8 of the reference). Furthermore ody (claim 10 of the reference). Therefore, the reference anti-	e, Yu teaches a method of icipates the present claims 1-10
body fragment, and that and the antibo	dv can be labeled (claims 6-8 of the reference) Furthermore	e, Yu teaches a method of icipates the present claims 1-10
body fragment, and that and the antibo	dv can be labeled (claims 6-8 of the reference) Furthermore	e, Yu teaches a method of icipates the present claims 1-10
body fragment, and that and the antibo	dv can be labeled (claims 6-8 of the reference) Furthermore	e, Yu teaches a method of icipates the present claims 1-10
body fragment, and that and the antibo	dv can be labeled (claims 6-8 of the reference) Furthermore	e, Yu teaches a method of icipates the present claims 1-10
body fragment, and that and the antibo	dv can be labeled (claims 6-8 of the reference) Furthermore	e, Yu teaches a method of icipates the present claims 1-10
body fragment, and that and the antibo	dv can be labeled (claims 6-8 of the reference) Furthermore	e, Yu teaches a method of icipates the present claims 1-10
body fragment, and that and the antibo	dv can be labeled (claims 6-8 of the reference) Furthermore	e, Yu teaches a method of icipates the present claims 1-10
body fragment, and that and the antibo	dv can be labeled (claims 6-8 of the reference) Furthermore	e, Yu teaches a method of icipates the present claims 1-10
body fragment, and that and the antibo	dv can be labeled (claims 6-8 of the reference) Furthermore	e, Yu teaches a method of icipates the present claims 1-10
body fragment, and that and the antibo	dv can be labeled (claims 6-8 of the reference) Furthermore	e, Yu teaches a method of icipates the present claims 1-10
body fragment, and that and the antibo	dv can be labeled (claims 6-8 of the reference) Furthermore	e, Yu teaches a method of icipates the present claims 1-10
body fragment, and that and the antibo	dv can be labeled (claims 6-8 of the reference) Furthermore	e, Yu teaches a method of icipates the present claims 1-10
body fragment, and that and the antibo	dv can be labeled (claims 6-8 of the reference) Furthermore	e, Yu teaches a method of icipates the present claims 1-10
body fragment, and that and the antibo	dv can be labeled (claims 6-8 of the reference) Furthermore	e, Yu teaches a method of icipates the present claims 1-10
body fragment, and that and the antibo	dv can be labeled (claims 6-8 of the reference) Furthermore	e, Yu teaches a method of icipates the present claims 1-10
body fragment, and that and the antibo	dv can be labeled (claims 6-8 of the reference) Furthermore	e, Yu teaches a method of icipates the present claims 1-10
body fragment, and that and the antibo	dv can be labeled (claims 6-8 of the reference) Furthermore	e, Yu teaches a method of icipates the present claims 1-10
body fragment, and that and the antibo	dv can be labeled (claims 6-8 of the reference) Furthermore	e, Yu teaches a method of icipates the present claims 1-10

Form PCT/ISA/237 (Box No. V) (April 2007)